Objective: Numerous studies have evaluated the use of procalcitonin guidance during different phases of antibiotics management (initiation, cessation, or a combination of both) in patients admitted to ICUs. Several meta-analyses have attempted to generate an overall effect of procalcitonin-guidance on patient outcomes. However, combining studies from different phases of antibiotics management may not be appropriate due to the risk of clinical heterogeneity. The purpose of this systematic review and meta-analysis was to evaluate the effect of procalcitonin-guided strategies in different phases of antibiotics use. Data Sources: We searched MEDLINE and EMBASE from inception until November 1, 2017. Study Selection: We included randomized controlled trials that evaluated procalcitonin guidance compared with usual care for management of antibiotics in critically ill adult patients. Data Extraction: We extracted study details, patient characteristics, procalcitonin algorithm, and outcomes. Data Synthesis: We included 15 studies, from 1,624 abstracts identified based on our search strategy (three initiation, nine cessation, and three mixed). The pooled risk ratio for short-term mortality for the initiation, cessation, and mixed procalcitonin strategies were 1.00 (95% CI, 0.86–1.15,;p = 0.91), 0.87 (95% CI, 0.77–0.98; p = 0.02), and 1.01 (95% CI, 0.80–1.29; p = 0.93), respectively. Procalcitonin for cessation and mixed strategies was associated with decrease antibiotics duration (–1.26 d [p
from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2CwBemm
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Lack of standard definitions of primary and secondary (non)responders after RYGB and SG makes it impossible to compare the litera...
-
We aimed (1) to describe the characteristics of patient–ventilator asynchrony in a population of critically ill children, (2) to describe th...
-
AbstractIntroductionVascular trauma data have been submitted to the American Association for the Surgery of Trauma PROspective Observational...
-
FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm https://www.mdedge.com/hematologynews/article/191723/rare-diseases/...
-
Note: Page numbers of article titles are in boldface type. from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2gDH2gG
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου